J&J paliperidone ER "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson's extended-release schizophrenia agent paliperidone is "approvable" Sept. 29; J&J says it will "work quickly to resolve the agency's questions." Earlier in September, the company had indicated that it expected an approvable decision. J&J submitted the follow-on compound to its blockbuster atypical antipsychotic Risperdal (risperidone) in December 2005 (1Pharmaceutical Approvals Monthly December 2005, In Brief)...
You may also be interested in...
Janssen hopes for Invega approval for the holidays
The Johnson & Johnson subsidiary's NDA for the antipsychotic Invega (paliperidone extended-release) has a Dec. 20 user fee goal date, J&J said Nov. 10 after submitting a response to FDA's Sept. 29 "approvable" letter (1Pharmaceutical Approvals Monthly October 2006, In Brief)...
J&J paliperidone NDA
Johnson & Johnson's Nov. 29 submission of the Risperdal (risperidone) follow-on paliperidone extended-release puts the firm on track to launch the schizophrenia treatment ahead of generic competition for Risperdal, which could lose exclusivity as early as mid-2008. The NDA is based on two Phase III trials, one of which is ongoing. Like risperidone, paliperidone is a dual dopamine D2 and serotonin 5-HT2 receptor antagonist...
Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: